R&D | Cutting-edge science and innovative research

News

AZ takes stake in Summit Therapeutics in $2bn deal

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

News

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

News

Test could end uncertainty in inherited muscle diseases

A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.

News

Wnt drug gives MSD first eye disease win after EyeBio deal

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

Oncology

Antibody drug conjugates – The time is now

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs ca

News

PacBio builds in short-read sequencing with $110m Apton buy

Gene sequencing specialist PacBio has reached an agreement to buy Apton Biosystems, boosting its position in short-read sequencing technology that has traditionally been d

News

Marrazzo to succeed Fauci as NIAID director

After months of deliberations, the National Institute of Allergy and Infectious Diseases (NIAID) has a new director to replace Dr Anthony Fauci, who held the role for 38 y

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

AZ takes stake in Summit Therapeutics in $2bn deal

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

News

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

Concept of AI overview of patient in clinical trial

How AI simulation could help de-risk obesity and cardiometab...

AI life sciences models allow researchers to explore different patient populations, protocols, and development strategies before a study starts.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

CAMP4 on a new class of ASO in gene under expression

CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study

Video

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.